September 26, 2024
Video
Panelists discuss how their approaches to treating patients with rheumatoid arthritis focus on personalized strategies that prioritize achieving remission while carefully monitoring safety and efficacy outcomes.
September 26, 2024
Video
Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.
September 19, 2024
Video
Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for patients whose initial positive response to TNFis declines over time.
September 19, 2024
Video
Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.